重新评估camrelizumab联合TACE +酪氨酸激酶抑制剂治疗不可切除肝癌的生存获益：TACE频率的低估影响

{"title":"重新评估camrelizumab联合TACE +酪氨酸激酶抑制剂治疗不可切除肝癌的生存获益：TACE频率的低估影响","authors":"Longshuang Wang, Jian Zhang, Jianfei Liu","doi":"10.1016/j.aohep.2025.102126","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":" ","pages":"102126"},"PeriodicalIF":4.4000,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Re-evaluating the survival benefit of adding camrelizumab to TACE plus tyrosine-kinase inhibitors in unresectable hepatocellular carcinoma: the undervalued influence of TACE frequency.\",\"authors\":\"Longshuang Wang, Jian Zhang, Jianfei Liu\",\"doi\":\"10.1016/j.aohep.2025.102126\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":7979,\"journal\":{\"name\":\"Annals of hepatology\",\"volume\":\" \",\"pages\":\"102126\"},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2025-09-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of hepatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.aohep.2025.102126\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.aohep.2025.102126","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}